로딩 중…
StockDiggingStockDigging

Apnimed Inc. Common Stock

APMD· NASDAQ
$28.11+3.77%
2026-09-17

Valuation Metrics

Apnimed Inc. Common Stock's Market Cap is $1.12B. Ranked #2406 of 3,121 in US market (top 77%), #975 of 1,463 on NASDAQ (top 67%) by Market Cap.

Investment Metrics(as of 2026-09-18)

MetricValue
Size
Market Cap$1.12B
Employees65
Performance
1M Return-11.63%
From 52W High-20.35%
1Y MDD-21.51%
Trading
Volume339,245 shares
Trading Value$10M

Company Info

CEO Kevin R. Lind
Employees 65
HQ Cambridge, US

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.